These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22955852)

  • 1. RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma.
    Kurashige J; Watanabe M; Iwatsuki M; Kinoshita K; Saito S; Nagai Y; Ishimoto T; Baba Y; Mimori K; Baba H
    Br J Cancer; 2012 Oct; 107(8):1233-8. PubMed ID: 22955852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer.
    Fujimoto D; Goi T; Koneri K; Hirono Y
    Oncotarget; 2018 Mar; 9(20):15208-15218. PubMed ID: 29632637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
    Qin RQ; Wen YS; Wang WP; Xi KX; Yu XY; Zhang LJ
    Med Oncol; 2016 Apr; 33(4):31. PubMed ID: 26922662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study.
    Gombodorj N; Yokobori T; Tanaka N; Suzuki S; Kuriyama K; Kumakura Y; Yoshida T; Sakai M; Sohda M; Baatar S; Miyazaki T; Nishiyama M; Shirabe K; Kuwano H
    J Surg Oncol; 2018 Jul; 118(1):101-108. PubMed ID: 30098297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K
    Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
    J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribophorin II promotes cell proliferation, migration, and invasion in esophageal cancer cells
    Li Y; Huang C; Bai Q; Yu J
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30940778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Nakamura Y; Yamaue H
    Surg Today; 2017 Jan; 47(1):65-73. PubMed ID: 27130464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.
    Wei B; Han Q; Xu L; Zhang X; Zhu J; Wan L; Jin Y; Qian Z; Wu J; Gao Y; Zhou J; Chen X
    BMC Cancer; 2015 Apr; 15():331. PubMed ID: 25925371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.
    Fujita Y; Yagishita S; Takeshita F; Yamamoto Y; Kuwano K; Ochiya T
    Oncotarget; 2015 Feb; 6(5):3335-45. PubMed ID: 25595901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
    Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
    World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma.
    Yang H; Li XD; Zhou Y; Ban X; Zeng TT; Li L; Zhang BZ; Yun J; Xie D; Guan XY; Li Y
    Oncotarget; 2015 Sep; 6(28):26079-89. PubMed ID: 26317793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
    Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
    Gao Y; Zhu J; Zhang X; Wu Q; Jiang S; Liu Y; Hu Z; Liu B; Chen X
    PLoS One; 2013; 8(1):e52589. PubMed ID: 23326344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
    Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
    Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RPN2 gene confers docetaxel resistance in breast cancer.
    Honma K; Iwao-Koizumi K; Takeshita F; Yamamoto Y; Yoshida T; Nishio K; Nagahara S; Kato K; Ochiya T
    Nat Med; 2008 Sep; 14(9):939-48. PubMed ID: 18724378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.
    Yamasaki M; Makino T; Masuzawa T; Kurokawa Y; Miyata H; Takiguchi S; Nakajima K; Fujiwara Y; Matsuura N; Mori M; Doki Y
    Br J Cancer; 2011 Feb; 104(4):707-13. PubMed ID: 21206495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.